Track the scientific, clinical, regulatory, patent, financing, deal, and conference signals that shape competitive landscapes, before they show up in static reports.
ASCO, AACR, ESMO, ASH and more, One Zyme reads every abstract, poster, and presentation and turns it into structured data you can search by competitor, drug, target, indication, phase, or conference.
Pharma and biotech conference presentations, structured for competitive monitoring.
One Zyme watches every competitor, asset, and indication across global sources at once, and the instant a meaningful pattern forms, it tells you, with the evidence and the implication attached.
Every signal is scored for strategic weight, so a Series C plus a Phase II start plus a priority review reads as one inflection, not three disconnected updates.
Each alert explains why it matters and what to do next, add to a shortlist, generate a company brief, or brief leadership, not just that something happened.
Because One Zyme reads primary sources directly, including local-language and regional registries, moves surface before they reach Western databases.
China is now one of the fastest-moving sources of competitive threats. One Zyme reads regulatory, clinical, corporate, scientific, patent, and local-language sources directly, surfacing the competitors and moves that Western databases miss entirely.
Spot competitor programs before they reach Western awareness.
Track competitors' IND filings and active China trials in real time.
Catch priority review and breakthrough designations as they're granted.
Map CNIPA families and cross-border filings to your watchlist.
Resolve subsidiaries, JVs, and related parties behind a competitor.
Catch ex-China licenses and collaborations as they form.
Map the patent landscape around an asset, mechanism, or modality, then pressure-test freedom to operate with blocking families, design-around paths, and expirations, every finding linked to its source.
One Zyme's patent analysis accelerates and structures freedom-to-operate review, mapping families, surfacing potential blocking art, and flagging design-around paths and expirations. It is not legal advice and does not replace a freedom-to-operate opinion from qualified patent counsel. Treat every finding as a starting point for your legal team.
Competitive monitoring used to mean Cortellis in one tab, Citeline in another, GlobalData, Evaluate, and Zymewire in three more, none of them talking to each other, and none of them watching China. One Zyme reads the same underlying corpus and resolves it into a single, cited, always-current intelligence layer.
Every CI workflow runs on the same agents, data, and evidence trail that power the rest of the platform.
Explore Models & Data →Get a strategic briefing tailored to your competitors, watchlists, and therapeutic priorities.
